MCID: LNG111
MIFTS: 55

Lung Non-Squamous Non-Small Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lung Non-Squamous Non-Small Cell Carcinoma

MalaCards integrated aliases for Lung Non-Squamous Non-Small Cell Carcinoma:

Name: Lung Non-Squamous Non-Small Cell Carcinoma 11 14
Non- Squamous Nsclc 11

Classifications:



External Ids:

Disease Ontology 11 DOID:0080521
NCIt 49 C135017

Summaries for Lung Non-Squamous Non-Small Cell Carcinoma

Disease Ontology: 11 A lung non-small cell carcinoma that is characterized by the lack of evidence of squamous differentiation.

MalaCards based summary: Lung Non-Squamous Non-Small Cell Carcinoma, also known as non- squamous nsclc, is related to lung cancer susceptibility 3 and exanthem. An important gene associated with Lung Non-Squamous Non-Small Cell Carcinoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Osimertinib and Afatinib have been mentioned in the context of this disorder. Affiliated tissues include lung, endothelial and brain, and related phenotypes are Decreased viability and Increased cell migration

Related Diseases for Lung Non-Squamous Non-Small Cell Carcinoma

Diseases related to Lung Non-Squamous Non-Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 29.3 VEGFA STK11 ROS1 KRAS KDR HRAS
2 exanthem 28.9 VEGFA PDCD1 MTUS2 MTUS1 KRAS HRAS
3 lung cancer 28.6 VEGFA TYMS STK11 ROS1 RET PDCD1
4 vulva verrucous carcinoma 10.4 PDCD1 CD274
5 thymus squamous cell carcinoma 10.4 MTUS2 MTUS1
6 heart leiomyosarcoma 10.3 EGFR ALK
7 urethra transitional cell carcinoma 10.3 EGFR ALK
8 pulmonary plasma cell granuloma 10.3 ROS1 ALK
9 trachea carcinoma in situ 10.3 KRAS HRAS
10 lymphoepithelioma-like carcinoma 10.3 EGFR CD274 ALK
11 common bile duct neoplasm 10.3 KRAS HRAS
12 signet ring lung adenocarcinoma 10.3 EML4 EGFR ALK
13 malignant giant cell tumor of the tendon sheath 10.3 ROS1 ALK
14 ampulla of vater benign neoplasm 10.3 KRAS HRAS
15 thyroid crisis 10.3 MTUS2 MTUS1
16 occipital lobe neoplasm 10.3 ROS1 EML4 ALK
17 bladder urachal carcinoma 10.3 KRAS HRAS
18 hepatic flexure cancer 10.3 KRAS HRAS
19 vaginal carcinosarcoma 10.3 KRAS HRAS
20 urachus cancer 10.3 KRAS HRAS
21 thyroid gland hurthle cell carcinoma 10.3 ROS1 EML4 ALK
22 epithelioid inflammatory myofibroblastic sarcoma 10.3 EML4 ALK
23 lung giant cell carcinoma 10.3 KRAS EGFR ALK
24 cryptogenic organizing pneumonia 10.3 MTUS2 MTUS1 CD274
25 main bronchus cancer 10.3 ROS1 RET ALK
26 descending colon cancer 10.3 KRAS HRAS
27 vaginal cancer 10.3 HRAS EGFR CD274
28 mucinous intrahepatic cholangiocarcinoma 10.3 KRAS HRAS
29 vulva squamous cell carcinoma 10.3 HRAS EGFR CD274
30 sigmoid neoplasm 10.3 KRAS HRAS
31 acneiform dermatitis 10.3 KRAS HRAS EGFR
32 mesenchymal cell neoplasm 10.3 ROS1 EML4 ALK
33 appendiceal neoplasm 10.3 KRAS HRAS
34 central nervous system hemangioma 10.3 VEGFA RET
35 dermatopathia pigmentosa reticularis 10.3 KRAS HRAS EGFR
36 orbital plasma cell granuloma 10.3 MTUS2 MTUS1 CTLA4
37 chronic orbital inflammation 10.3 MTUS2 MTUS1 CTLA4
38 pancreatic mucinous cystadenoma 10.3 KRAS HRAS
39 autoimmune myocarditis 10.3 MTUS2 CTLA4 CD274
40 transverse colon cancer 10.3 KRAS HRAS
41 lymphocytic colitis 10.3 PDCD1 MTUS2 CTLA4
42 lung adenoma 10.3 KRAS HRAS EGFR
43 malignant dermis tumor 10.2 HRAS CTLA4 CD274
44 vulvar melanoma 10.2 HRAS CTLA4 CD274
45 malignant skin fibrous histiocytoma 10.2 HRAS CTLA4 CD274
46 respiratory system benign neoplasm 10.2 KRAS HRAS EGFR
47 noonan syndrome-like disorder with loose anagen hair 1 10.2 KRAS HRAS
48 colon adenoma 10.2 KRAS HRAS EGFR
49 testicular spermatocytic seminoma 10.2 RET HRAS
50 central nervous system vasculitis 10.2 MTUS2 MTUS1 CTLA4

Graphical network of the top 20 diseases related to Lung Non-Squamous Non-Small Cell Carcinoma:



Diseases related to Lung Non-Squamous Non-Small Cell Carcinoma

Symptoms & Phenotypes for Lung Non-Squamous Non-Small Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

25 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.76 HRAS KRAS EGFR
2 Decreased viability GR00055-A-2 10.76 HRAS KRAS EGFR
3 Decreased viability GR00055-A-3 10.76 KRAS
4 Decreased viability GR00106-A-0 10.76 KRAS
5 Decreased viability GR00221-A-1 10.76 HRAS KDR KRAS RET ROS1 ALK
6 Decreased viability GR00221-A-2 10.76 HRAS KDR KRAS RET ROS1
7 Decreased viability GR00221-A-3 10.76 HRAS KDR ERBB2
8 Decreased viability GR00221-A-4 10.76 KDR RET ALK EGFR ERBB2
9 Decreased viability GR00249-S 10.76 KDR ROS1 ALK
10 Decreased viability GR00301-A 10.76 KRAS RET
11 Decreased viability GR00342-S-1 10.76 ROS1
12 Decreased viability GR00381-A-1 10.76 KRAS
13 Decreased viability GR00402-S-2 10.76 RET
14 Increased cell migration GR00055-A-1 9.26 KDR
15 Increased cell migration GR00055-A-3 9.26 KDR
16 Increased cell viability after pRB stimulation GR00230-A-1 8.92 EGFR ERBB2 RET STK11

MGI Mouse Phenotypes related to Lung Non-Squamous Non-Small Cell Carcinoma:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.36 ABCG2 ALK CD274 CTLA4 EGFR ERBB2
2 neoplasm MP:0002006 10.32 ALK EGFR ERBB2 HRAS KRAS MTUS1
3 normal MP:0002873 10.31 ABCG2 ALK CTLA4 EGFR ERBB2 HRAS
4 endocrine/exocrine gland MP:0005379 10.27 ALK CTLA4 EGFR ERBB2 HRAS KRAS
5 no phenotypic analysis MP:0003012 10.26 CD274 EGFR HRAS KDR KRAS PDCD1LG2
6 cellular MP:0005384 10.21 ABCG2 CD274 EGFR ERBB2 KDR KRAS
7 renal/urinary system MP:0005367 10.2 ABCG2 EGFR HRAS KRAS MTUS1 PDCD1
8 muscle MP:0005369 10.19 EGFR ERBB2 HRAS KDR KRAS PDCD1
9 digestive/alimentary MP:0005381 10.18 ABCG2 CTLA4 EGFR ERBB2 HRAS KRAS
10 immune system MP:0005387 10.15 ABCG2 CD274 CTLA4 EGFR KDR KRAS
11 cardiovascular system MP:0005385 10.14 CTLA4 EGFR ERBB2 HRAS KDR KRAS
12 liver/biliary system MP:0005370 10.13 ABCG2 CTLA4 EGFR KDR KRAS PDCD1
13 respiratory system MP:0005388 10.06 ALK CTLA4 EGFR ERBB2 HRAS KDR
14 craniofacial MP:0005382 10 EGFR ERBB2 HRAS KDR KRAS STK11
15 skeleton MP:0005390 10 ALK CD274 CTLA4 EGFR ERBB2 HRAS
16 hematopoietic system MP:0005397 9.97 ABCG2 CD274 CTLA4 EGFR ERBB2 KDR
17 mortality/aging MP:0010768 9.86 ALK CD274 CTLA4 EGFR EML4 ERBB2
18 integument MP:0010771 9.36 ABCG2 ALK CD274 CTLA4 EGFR ERBB2

Drugs & Therapeutics for Lung Non-Squamous Non-Small Cell Carcinoma

Drugs for Lung Non-Squamous Non-Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Osimertinib Approved Phase 4 1421373-65-0 71496458
2
Afatinib Approved Phase 4 439081-18-2, 850140-72-6 53445376 10184653
3
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
4
Erlotinib Approved, Investigational Phase 3 183319-69-9, 183321-74-6 176870
5
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
6
Maleic acid Experimental, Investigational Phase 3 110-16-7, 110-17-8 444266 444972
7 Antiviral Agents Phase 3
8 Anti-Infective Agents Phase 3
9 Immunoglobulins Phase 3
10 Antimetabolites Phase 3
11 Antibodies Phase 3
12 Immunosuppressive Agents Phase 3
13 Immunologic Factors Phase 3
14 Endothelial Growth Factors Phase 3
15
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
16
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
17
Ramucirumab Approved, Investigational Phase 2 947687-13-0
18
Sargramostim Approved, Investigational Phase 2 123774-72-1
19
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
20
Avelumab Approved, Investigational Phase 2 1537032-82-8
21
Ipilimumab Approved Phase 2 477202-00-9
22
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
23
Ceritinib Approved Phase 2 1032900-25-6 57379345
24
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203
25
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
26
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
27
Nivolumab Approved Phase 2 946414-94-4
28
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
29
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
30
Crizotinib Approved, Investigational Phase 2 877399-52-5 11626560
31
Durvalumab Approved, Investigational Phase 2 1428935-60-7
32
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
34
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
35
Lexatumumab Investigational Phase 2 845816-02-6
36
Molgramostim Investigational Phase 2 99283-10-0
37
Rivoceranib Investigational Phase 2 811803-05-1 11315474
38
Pevonedistat Investigational Phase 2 905579-51-3 49831043
39
Ensartinib Investigational Phase 2 1365267-27-1, 1370651-20-9 56960447
40
Imetelstat Investigational Phase 2 868169-64-6
41 Vaccines Phase 2
42 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
43 Folic Acid Antagonists Phase 2
44 Folate Phase 2
45 Vitamin B9 Phase 2
46 Vitamin B Complex Phase 2
47 Immunoglobulins, Intravenous Phase 2
48 Immune Checkpoint Inhibitors Phase 2
49 Immunoglobulin G Phase 2
50 Protein Kinase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control. Unknown status NCT03768037 Phase 4 Anlotinib plus Pemetrexed;Pemetrexed
2 An Open, Single-arm, Multi-center Study of Anlotinib in Advanced Non-squamous NSCLC Patients in the Elderly Without Systemic Chemotherapy Unknown status NCT03778853 Phase 4 Anlotinib Hydrochloride
3 An Open, Single-arm, Multi-center Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line Chemotherapy Unknown status NCT03755869 Phase 4 Anlotinib
4 AFAMOSI: Prospective, Randomized, Multicenter Phase IV Study to Evaluate the Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients With EGFRmutated/T790M Mutation Negative Non-squamous NSCLC in the First-line Setting Recruiting NCT04413201 Phase 4 Afatinib;Osimertinib
5 A Randomized, Double-blind Study of the Effect of Avastin Plus Cisplatin and Gemcitabine or Placebo Plus Cisplatin and Gemcitabine on Progression-free Survival in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC Completed NCT00806923 Phase 3 Cisplatin;Gemcitabine;Placebo;bevacizumab [Avastin]
6 Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC Completed NCT02954172 Phase 3 Bevacizumab in Combination With Paclitaxel/Carboplatin;IBI305 in Combination with Paclitaxel/Carboplatin
7 A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin Completed NCT02810457 Phase 3 FKB238 (bevacizumab);Avastin (bevacizumab);Paclitaxel;Carboplatin
8 Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Completed NCT01107626 Phase 3 Paclitaxel;Carboplatin;Pemetrexed Disodium Heptahydrate
9 Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Recruiting NCT04181060 Phase 3 Osimertinib
10 EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis Recruiting NCT03793179 Phase 3 Carboplatin;Pemetrexed
11 Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO) Recruiting NCT04267848 Phase 3 Carboplatin;Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Pemetrexed Disodium
12 A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy Recruiting NCT04447118 Phase 3 Pyrotinib;Docetaxel
13 A Phase 3,Randomized,Open,Parallel Controlled, Multi-center Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab as a First-line Treatment on Patient With Advanced Non-squamous NSCLC Recruiting NCT05346952 Phase 3 TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection
14 A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment Recruiting NCT05184712 Phase 3 AK112 Injection;Placebo Injection
15 Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT02193282 Phase 3 Erlotinib Hydrochloride
16 A RANDOMIZED, DOUBLE-BLIND BRIDGING SAFETY AND EFFICACY STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF CHINESE PARTICIPANTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER Terminated NCT04325698 Phase 3 PF-06439535 (CN);Bevacizumab-EU;Paclitaxel;Carboplatin
17 A Randomized, Double-blind, Phase 3 Bridging Study Evaluating the Safety and Efficacy of ABP 215 Compared With Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer Withdrawn NCT04466917 Phase 3 ABP 215;Bevacizumab;Paclitaxel;Carboplatin
18 A Randomized Phase II Trial of Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib Unknown status NCT04358562 Phase 2 Gefitinib;Anlotinib
19 Anlotinib Combined With Docetaxel as Second-line Treatment of Patients With Wild-type Advanced Non-squamous NSCLC Unknown status NCT03750916 Phase 2 Anlotinib Hydrochloride plus Docetaxel
20 A Phase Ⅱ Randomized Controlled Trial to Compare Gefitinib With Docetaxel as Second-line Therapy for Advanced or Metastatic Non-squamous NSCLC Patients With Wild-type EGFR Unknown status NCT01755923 Phase 2 Gefitinib;Docetaxel
21 A Randomized Phase II Trial of Erlotinib Alone or in Combination With Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations Completed NCT01532089 Phase 2 Erlotinib;Erlotinib Hydrochloride
22 A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy Completed NCT02047344 Phase 2 Antroquinonol
23 Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabin/Cisplatin Plus Bevacizumab Completed NCT00536640 Phase 2 Erlotinib;Bevacizumab;Gemcitabine;Cisplatin
24 A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC Completed NCT00251524 Phase 2 Bevacizumab, Oxaliplatin, Pemetrexed
25 Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
26 A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC Completed NCT01496742 Phase 2 Placebo;RO5490258;bevacizumab [Avastin];cisplatin/carboplatin;paclitaxel;pemetrexed
27 A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC Recruiting NCT04310007 Phase 2 Cabozantinib S-malate;Docetaxel;Gemcitabine Hydrochloride;Nab-paclitaxel;Paclitaxel
28 A Phase Ib/II Trial to Evaluate Safety, Tolerability and Efficacy of Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for Patients With EGFR-Mutant Non-Small Cell Lung Cancer Recruiting NCT05017025 Phase 1, Phase 2 Aurora A Kinase Inhibitor LY3295668;Osimertinib
29 A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY) Recruiting NCT04625647 Phase 2 Sotorasib
30 A Phase II Randomized Study of Safety and Efficacy of a Multiple Antigen Vaccine (STEMVAC) in NonSquamous Non-Small-Cell Lung Cancer Patients Recruiting NCT05242965 Phase 2
31 A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer Recruiting NCT05198830 Phase 2 Cisplatin;Methoxyamine;Pemetrexed
32 A Single-Arm Phase II Trial of Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy Recruiting NCT04670913 Phase 2 Camrelizumab;Apatinib
33 A Randomized, Phase II Study of Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed and Carboplatin (PC) for Metastatic Non-Squamous NSCLC Recruiting NCT04163432 Phase 2 Durvalumab;Pemetrexed;Carboplatin
34 TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked Recruiting NCT03786692 Phase 2 Arm A;Arm B
35 Phase II Randomized Trial of Carboplatin/Cisplatin+Pemetrexed+PD-1 Inhibitor+/- Bevacizumab in Stage IV Non-squamous NSCLC Recruiting NCT05267366 Phase 2 PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed
36 A Phase II Two Cohorts Prospective Study to Evaluate the Efficacy and Safety of Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in Non-squamous NSCLC With EGFR Sensitizing Mutation Who Failed EGFR TKI Therapy Recruiting NCT04405674 Phase 2 Tislelizumab;Carboplatin;Pemetrexed;Bevacizumab;Nab paclitaxel
37 A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC Recruiting NCT04958811 Phase 2 Tiragolumab;Atezolizumab;Bevacizumab
38 A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study) Active, not recruiting NCT04173507 Phase 2 Avelumab;Talazoparib;Talazoparib Tosylate
39 A Phase 2 Study of MLN4924 (Pevonedistat) in Combination With Carboplatin and Paclitaxel in Advanced NSCLC Previously Treated With Immunotherapy Active, not recruiting NCT03965689 Phase 2 Carboplatin;Paclitaxel;Pevonedistat
40 A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC Active, not recruiting NCT03468985 Phase 2 Cabozantinib;Cabozantinib S-malate
41 A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol Active, not recruiting NCT03737994 Phase 2 Alectinib;Brigatinib;Carboplatin;Ceritinib;Cisplatin;Crizotinib;Ensartinib;Lorlatinib;Pemetrexed
42 A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance Active, not recruiting NCT04245085 Phase 2 Atezolizumab;Bevacizumab;Carboplatin;Paclitaxel;Pemetrexed
43 A Phase 2 Trial of Pembrolizumab in Metastatic Non-squamous NSCLC Examining Circulating Tumor DNA Levels as a Surrogate Biomarker of Response Active, not recruiting NCT02955758 Phase 2
44 Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed for Untreated EGFR+ and High PD-L1 Expression Non-squamous NSCLC :a Phase II, Single-center, Single Arm Study Not yet recruiting NCT05394233 Phase 2 Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed
45 A Single-Arm Phase 2 Study to Investigate Bintrafusp Alfa With Platinum-Pemetrexed for TKI-Resistant EGFR-Mutant NSCLC Terminated NCT04971187 Phase 2 Bintrafusp Alfa;Pemetrexed;Carboplatin;Cisplatin
46 A Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy Terminated NCT02452463 Phase 2 Nintedanib
47 A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination With Paclitaxel and Carboplatin for Advanced Non-squamous Non-small Cell Lung Cancer Terminated NCT00369070 Phase 2 AMG 706;Paclitaxel;Carboplatin
48 A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor Terminated NCT02454842 Phase 2 TH-4000 (Tarloxotinib)
49 Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor Terminated NCT03041181 Phase 2 Docetaxel;Nivolumab;Gemcitabine;Pemetrexed
50 S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy Terminated NCT02134912 Phase 2 crizotinib;pemetrexed disodium

Search NIH Clinical Center for Lung Non-Squamous Non-Small Cell Carcinoma

Genetic Tests for Lung Non-Squamous Non-Small Cell Carcinoma

Anatomical Context for Lung Non-Squamous Non-Small Cell Carcinoma

Organs/tissues related to Lung Non-Squamous Non-Small Cell Carcinoma:

MalaCards : Lung, Endothelial, Brain, Lymph Node, Thyroid, Bone, Neutrophil

Publications for Lung Non-Squamous Non-Small Cell Carcinoma

Articles related to Lung Non-Squamous Non-Small Cell Carcinoma:

(show top 50) (show all 473)
# Title Authors PMID Year
1
Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis. 62
36128737 2022
2
A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. 62
35995696 2022
3
Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety. 62
35851702 2022
4
Is video-assisted thoracoscopic surgery comparable with thoracotomy in perioperative and long-term survival outcomes for non-small-cell lung cancer after neoadjuvant treatment? 62
36409029 2022
5
Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer. 62
36413862 2022
6
Prognostic value of Beclin 1, EGFR and ALK in non-squamous non-small cell lung cancer. 62
36401689 2022
7
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. 62
36008722 2022
8
Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. 62
35988454 2022
9
First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study. 62
36314347 2022
10
Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC. 62
35838647 2022
11
Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis. 62
35641819 2022
12
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. 62
36027916 2022
13
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC. 62
36027917 2022
14
EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway - A nationwide retrospective cohort study. 62
36155129 2022
15
Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. 62
35598202 2022
16
Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis. 62
35290596 2022
17
Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China. 62
36194670 2022
18
Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations. 62
35835883 2022
19
Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy. 62
35739333 2022
20
Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis. 62
35836506 2022
21
Extracellular Vesicle-Based Bronchoalveolar Lavage Fluid Liquid Biopsy for EGFR Mutation Testing in Advanced Non-Squamous NSCLC. 62
35681723 2022
22
Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. 62
35331641 2022
23
Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction. 62
34470722 2022
24
Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study. 62
35349855 2022
25
Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. 62
35532791 2022
26
Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications. 62
34997651 2022
27
Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China. 62
32737070 2022
28
Sintilimab for the treatment of non-small cell lung cancer. 62
35436956 2022
29
Sugemalimab: First Approval. 62
35298827 2022
30
A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. 62
35248841 2022
31
MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. 62
35277462 2022
32
Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis. 62
35329978 2022
33
Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice. 62
35323374 2022
34
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial. 62
35051725 2022
35
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. 62
35105329 2022
36
A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion. 62
35080187 2022
37
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. 62
35038432 2022
38
Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up. 62
35042754 2022
39
Molecular analysis in cytological samples obtained by endobronchial or oesophageal ultrasound guided needle aspiration in non-small cell lung cancer. 62
32507497 2022
40
Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis. 62
35799785 2022
41
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists. 62
34921524 2022
42
The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer. 62
35923926 2022
43
Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features. 62
35479081 2022
44
Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. 62
35060001 2022
45
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric study. 62
35694190 2022
46
Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer. 62
35342321 2022
47
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50. 62
36033444 2022
48
Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer. 62
36172187 2022
49
Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study. 62
36275698 2022
50
MYL-1402O: A Bevacizumab Biosimilar. 62
34910269 2022

Variations for Lung Non-Squamous Non-Small Cell Carcinoma

Cosmic variations for Lung Non-Squamous Non-Small Cell Carcinoma:

8 (show top 50) (show all 17775)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM98616023 ZZEF1 lung,NS,carcinoma,small cell carcinoma c.4892G>T p.G1631V 17:4059282-4059282 6
2 COSM132740059 ZYG11B lung,NS,carcinoma,small cell carcinoma c.1635G>C p.M545I 1:52801968-52801968 6
3 COSM86240454 ZYG11B lung,NS,carcinoma,small cell carcinoma c.1635G>C p.M545I 1:52801968-52801968 6
4 COSM86919234 ZSWIM4 lung,NS,carcinoma,small cell carcinoma c.944G>T p.R315L 19:13809152-13809152 6
5 COSM88262283 ZRSR2 lung,NS,carcinoma,small cell carcinoma c.1180G>A p.E394K 23:15822973-15822973 6
6 COSM143073175 ZRANB2 lung,NS,carcinoma,small cell carcinoma c.17T>C p.F6S 1:71080979-71080979 6
7 COSM97720347 ZRANB2 lung,NS,carcinoma,small cell carcinoma c.17T>C p.F6S 1:71080979-71080979 6
8 COSM87171618 ZRANB2 lung,NS,carcinoma,small cell carcinoma c.17T>C p.F6S 1:71080979-71080979 6
9 COSM137271685 ZP2 lung,NS,carcinoma,small cell carcinoma c.1581C>T p.P527= 16:21201455-21201455 6
10 COSM137165710 ZP2 lung,NS,carcinoma,small cell carcinoma c.1608C>T p.P536= 16:21201455-21201455 6
11 COSM131896932 ZNF84 lung,NS,carcinoma,small cell carcinoma c.239-5340A>G p.? 12:133057739-133057739 6
12 COSM101262318 ZNF84 lung,NS,carcinoma,small cell carcinoma c.1024A>G p.T342A 12:133057739-133057739 6
13 COSM91416826 ZNF84 lung,NS,carcinoma,small cell carcinoma c.1024A>G p.T342A 12:133057739-133057739 6
14 COSM133556674 ZNF84 lung,NS,carcinoma,small cell carcinoma c.1021A>G p.T341A 12:133057739-133057739 6
15 COSM130336034 ZNF84 lung,NS,carcinoma,small cell carcinoma c.1024A>G p.T342A 12:133057739-133057739 6
16 COSM98062407 ZNF831 lung,NS,carcinoma,small cell carcinoma c.1027G>C p.D343H 20:59192046-59192046 6
17 COSM149927805 ZNF831 lung,NS,carcinoma,small cell carcinoma c.1027G>C p.D343H 20:59192046-59192046 6
18 COSM92021621 ZNF804B lung,NS,carcinoma,small cell carcinoma c.522C>A p.P174= 7:89333504-89333504 6
19 COSM142170486 ZNF804B lung,NS,carcinoma,small cell carcinoma c.273C>A p.P91= 7:89333504-89333504 6
20 COSM142179504 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3504G>C p.L1168= 7:89336735-89336735 6
21 COSM142171430 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3412G>C p.A1138P 7:89336643-89336643 6
22 COSM92048538 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3753G>C p.L1251= 7:89336735-89336735 6
23 COSM92024942 ZNF804B lung,NS,carcinoma,small cell carcinoma c.3661G>C p.A1221P 7:89336643-89336643 6
24 COSM88575001 ZNF804A lung,NS,carcinoma,small cell carcinoma c.862A>T p.K288* 2:184936258-184936258 6
25 COSM88576053 ZNF804A lung,NS,carcinoma,small cell carcinoma c.3281C>T p.S1094F 2:184938677-184938677 6
26 COSM143615605 ZNF804A lung,NS,carcinoma,small cell carcinoma c.607A>T p.K203* 2:184936258-184936258 6
27 COSM143615950 ZNF804A lung,NS,carcinoma,small cell carcinoma c.3026C>T p.S1009F 2:184938677-184938677 6
28 COSM84362584 ZNF777 lung,NS,carcinoma,small cell carcinoma c.1998C>T p.C666= 7:149432274-149432274 6
29 COSM91557035 ZNF746 lung,NS,carcinoma,small cell carcinoma c.887C>T p.A296V 7:149475432-149475432 6
30 COSM151200494 ZNF746 lung,NS,carcinoma,small cell carcinoma c.932C>T p.A311V 7:149475432-149475432 6
31 COSM114445791 ZNF746 lung,NS,carcinoma,small cell carcinoma c.890C>T p.A297V 7:149475432-149475432 6
32 COSM97007058 ZNF711 lung,NS,carcinoma,small cell carcinoma c.173A>T p.D58V 23:85255352-85255352 6
33 COSM87004058 ZNF711 lung,NS,carcinoma,small cell carcinoma c.1371G>T p.E457D 23:85270913-85270913 6
34 COSM96524071 ZNF711 lung,NS,carcinoma,small cell carcinoma c.1371G>T p.E457D 23:85270913-85270913 6
35 COSM87004493 ZNF711 lung,NS,carcinoma,small cell carcinoma c.173A>T p.D58V 23:85255352-85255352 6
36 COSM97006621 ZNF711 lung,NS,carcinoma,small cell carcinoma c.1509G>T p.E503D 23:85270913-85270913 6
37 COSM96524396 ZNF711 lung,NS,carcinoma,small cell carcinoma c.173A>T p.D58V 23:85255352-85255352 6
38 COSM130605261 ZNF7 lung,NS,carcinoma,small cell carcinoma c.701G>C p.G234A 8:144842096-144842096 6
39 COSM89464457 ZNF7 lung,NS,carcinoma,small cell carcinoma c.281-3883G>C p.? 8:144842096-144842096 6
40 COSM129405109 ZNF7 lung,NS,carcinoma,small cell carcinoma c.248-3883G>C p.? 8:144842096-144842096 6
41 COSM110827987 ZNF7 lung,NS,carcinoma,small cell carcinoma c.1022G>C p.G341A 8:144842096-144842096 6
42 COSM130688921 ZNF7 lung,NS,carcinoma,small cell carcinoma c.989G>C p.G330A 8:144842096-144842096 6
43 COSM141336221 ZNF667 lung,NS,carcinoma,small cell carcinoma c.132G>T p.L44F 19:56460717-56460717 6
44 COSM122146768 ZNF667 lung,NS,carcinoma,small cell carcinoma c.132G>T p.L44F 19:56460717-56460717 6
45 COSM85394970 ZNF667 lung,NS,carcinoma,small cell carcinoma c.132G>T p.L44F 19:56460717-56460717 6
46 COSM92174992 ZNF660 lung,NS,carcinoma,small cell carcinoma c.575G>A p.C192Y 3:44594768-44594768 6
47 COSM86006104 ZNF653 lung,NS,carcinoma,small cell carcinoma c.808C>T p.P270S 19:11487655-11487655 6
48 COSM86006115 ZNF653 lung,NS,carcinoma,small cell carcinoma c.346C>T p.R116W 19:11496163-11496163 6
49 COSM105713312 ZNF638 lung,NS,carcinoma,small cell carcinoma c.1926G>A p.K642= 2:71365637-71365637 6
50 COSM105035820 ZNF638 lung,NS,carcinoma,small cell carcinoma c.1926G>A p.K642= 2:71365637-71365637 6

Expression for Lung Non-Squamous Non-Small Cell Carcinoma

Search GEO for disease gene expression data for Lung Non-Squamous Non-Small Cell Carcinoma.

Pathways for Lung Non-Squamous Non-Small Cell Carcinoma

Pathways related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 ALK EGFR ERBB2 HRAS KDR KRAS
2
Show member pathways
13.82 VEGFA PDCD1 KRAS KDR HRAS ERBB2
3 13.76 ALK CD274 EGFR ERBB2 HRAS KDR
4
Show member pathways
13.71 VEGFA ROS1 KRAS KDR HRAS ERBB2
5
Show member pathways
13.65 ALK EGFR ERBB2 HRAS KDR KRAS
6
Show member pathways
13.55 VEGFA ROS1 KRAS KDR HRAS ERBB2
7
Show member pathways
13.42 ROS1 KRAS KDR HRAS ERBB2 EGFR
8
Show member pathways
13.35 ALK EGFR EML4 ERBB2 HRAS KDR
9
Show member pathways
13.33 ROS1 KRAS KDR HRAS ERBB2 EGFR
10
Show member pathways
13.22 VEGFA ROS1 KRAS KDR HRAS ERBB2
11
Show member pathways
13.06 STK11 KRAS KDR HRAS EGFR ALK
12
Show member pathways
12.96 ALK EGFR ERBB2 KDR ROS1
13
Show member pathways
12.94 EGFR HRAS KDR KRAS STK11 VEGFA
14 12.73 ALK CD274 EGFR ERBB2 HRAS KDR
15 12.7 VEGFA KDR HRAS EGFR CD274
16
Show member pathways
12.54 VEGFA KRAS KDR HRAS ERBB2 EML4
17
Show member pathways
12.5 KRAS HRAS ERBB2 EGFR
18
Show member pathways
12.47 KRAS HRAS ERBB2 EGFR
19
Show member pathways
12.43 VEGFA KRAS KDR HRAS EGFR
20
Show member pathways
12.41 VEGFA KDR HRAS EGFR
21
Show member pathways
12.41 VEGFA KRAS KDR HRAS
22
Show member pathways
12.4 PDCD1LG2 PDCD1 CTLA4 CD274
23
Show member pathways
12.4 KRAS KDR HRAS ERBB2 EGFR
24
Show member pathways
12.32 VEGFA KRAS KDR HRAS
25
Show member pathways
12.32 ALK EGFR ERBB2 HRAS KDR KRAS
26 12.25 KRAS KDR HRAS EGFR
27
Show member pathways
12.25 KRAS HRAS ERBB2 EGFR
28 12.24 VEGFA KDR HRAS ERBB2 EGFR
29
Show member pathways
12.19 KRAS KDR HRAS ERBB2 EGFR
30
Show member pathways
12.17 VEGFA KRAS KDR HRAS EGFR
31
Show member pathways
12.15 KRAS HRAS ERBB2 EGFR
32 12.13 VEGFA STK11 KRAS EGFR
33
Show member pathways
12.11 VEGFA KRAS KDR HRAS
34
Show member pathways
12.06 KRAS HRAS ERBB2 EGFR
35 12.05 STK11 KRAS KDR ERBB2 EGFR
36
Show member pathways
12.03 KRAS HRAS ERBB2 EGFR
37 12.02 ROS1 RET KDR ERBB2 EGFR ALK
38 11.96 VEGFA KRAS HRAS EGFR
39
Show member pathways
11.95 KRAS HRAS ERBB2 EGFR
40 11.93 KRAS HRAS ERBB2
41
Show member pathways
11.91 KRAS HRAS EGFR
42
Show member pathways
11.86 EGFR ERBB2 VEGFA
43 11.83 VEGFA KDR EGFR
44
Show member pathways
11.8 PDCD1LG2 PDCD1 CD274
45
Show member pathways
11.76 HRAS KDR KRAS RET
46
Show member pathways
11.73 EGFR TYMS VEGFA
47 11.6 EGFR KDR VEGFA
48 11.59 VEGFA KDR EGFR
49 11.58 KRAS HRAS ERBB2 EGFR
50
Show member pathways
11.57 KRAS KDR HRAS

GO Terms for Lung Non-Squamous Non-Small Cell Carcinoma

Cellular components related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.22 ABCG2 ALK CD274 CTLA4 EGFR ERBB2
2 membrane GO:0016020 10.22 ABCG2 ALK CD274 CTLA4 EGFR EML4
3 plasma membrane GO:0005886 10.18 ROS1 RET KDR ERBB2 EGFR CTLA4
4 plasma membrane GO:0005887 10.18 ROS1 RET KDR ERBB2 EGFR CTLA4
5 receptor complex GO:0043235 9.4 ROS1 RET KDR ERBB2 EGFR ALK

Biological processes related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.51 ALK CD274 EGFR ERBB2 HRAS KRAS
2 positive regulation of cell population proliferation GO:0008284 10.38 VEGFA KRAS KDR HRAS ERBB2 EGFR
3 cell surface receptor signaling pathway GO:0007166 10.3 PDCD1LG2 HRAS ERBB2 EGFR CD274
4 protein phosphorylation GO:0006468 10.26 ALK EGFR ERBB2 KDR RET ROS1
5 positive regulation of cell migration GO:0030335 10.23 VEGFA RET KDR HRAS EGFR CD274
6 protein autophosphorylation GO:0046777 10.21 STK11 KDR ERBB2 EGFR ALK
7 positive regulation of protein phosphorylation GO:0001934 10.21 EGFR ERBB2 HRAS KDR KRAS VEGFA
8 MAPK cascade GO:0000165 10.19 EGFR HRAS KRAS RET
9 positive regulation of MAPK cascade GO:0043410 10.14 VEGFA RET KDR HRAS ERBB2 ALK
10 positive regulation of MAP kinase activity GO:0043406 10.1 VEGFA HRAS ERBB2 EGFR
11 phosphorylation GO:0016310 10.08 ALK EGFR ERBB2 KDR RET ROS1
12 negative regulation of T cell proliferation GO:0042130 10.06 PDCD1LG2 CTLA4 CD274
13 peptidyl-tyrosine phosphorylation GO:0018108 10.06 ALK EGFR ERBB2 KDR RET ROS1
14 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.03 ROS1 RET KDR ERBB2 EGFR ALK
15 positive regulation of epithelial cell proliferation GO:0050679 10.02 VEGFA KDR HRAS ERBB2 EGFR
16 regulation of ERK1 and ERK2 cascade GO:0070372 10.01 ROS1 ERBB2 EGFR
17 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.87 VEGFA KDR
18 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.86 VEGFA KDR
19 positive regulation of phosphorylation GO:0042327 9.85 VEGFA KDR EGFR
20 positive regulation of kinase activity GO:0033674 9.73 ROS1 RET KDR ERBB2 EGFR ALK
21 peptidyl-tyrosine autophosphorylation GO:0038083 9.7 ALK EGFR KDR ROS1
22 multicellular organism development GO:0007275 9.1 ROS1 RET KDR ERBB2 EGFR ALK

Molecular functions related to Lung Non-Squamous Non-Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 10.02 TYMS STK11 ROS1 RET KDR GART
2 protein tyrosine kinase activity GO:0004713 9.93 ALK EGFR ERBB2 KDR RET ROS1
3 kinase activity GO:0016301 9.87 STK11 ROS1 RET KDR ERBB2 EGFR
4 protein kinase activity GO:0004672 9.8 STK11 ROS1 RET KDR ERBB2 EGFR
5 nucleotide binding GO:0000166 9.7 STK11 ROS1 RET KRAS KDR HRAS
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.4 ROS1 RET KDR ERBB2 EGFR ALK

Sources for Lung Non-Squamous Non-Small Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....